Genelux (NASDAQ:GNLX) Lifted to Strong-Buy at Roth Capital

Roth Capital upgraded shares of Genelux (NASDAQ:GNLX – Free Report) to a strong-buy rating in a report published on Tuesday morning, Zacks.com reports. A number of other brokerages also recently commented on GNLX. Benchmark reduced their target price on shares of Genelux from $30.00 to $25.00 and set a speculative buy rating on the stock […]

Leave a Reply

Your email address will not be published.

Previous post Ascendis Pharma A/S (NASDAQ:ASND) Upgraded to “Strong-Buy” by Evercore ISI
Next post Aptevo Therapeutics (NASDAQ:APVO) Coverage Initiated at StockNews.com